• Medical_Professionals
• Medical_students
• Nurses

Engaging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment, and Treatment (GAIN) is an innovative longitudinal educational initiative consisting of pulmonology, thoracic surgery, pathology, and oncology clinicians engaged in various live, enduring, and practice improvement efforts.

This educational curriculum is designed for health-care providers to improve their knowledge, skills, and competence in the assessment and management of non-small cell lung cancer (NSCLC).

Content will address management of locally advanced and metastatic lung cancer by using multidisciplinary and multimodality approaches. These include conventional chemotherapy and biomarker-driven therapy, including immune checkpoint inhibitors that target to unleash or enhance preexisting anticancer immune responses. Examples of these immunotherapies target PD-1 antibodies, PD-L1 antibodies, and CTLA-4 antibodies. Genotype-driven therapy will be addressed by discussing agents that target genetic abnormalities, including but not limited to: EGFR, KRAS, BRAF mutations, and ALK and ROS1 translocations.

GAIN Live Summits feature an experiential learning theory-based instructional design with pre-course learning activities, flipped classroom, and interactive, participatory group and team-based workshop sessions.

Target Audience

This initiative will engage the following health-care professional audiences who focus on NSCLC diagnosis and patient care:

Pulmonology

Thoracic Surgery

Pathology

Medical Oncology

Relevant Physician Assistants and Nurse Practitioners

Nurse Navigators and Case Managers

Improve overall knowledge and competence in relation to tumor biomarkers associated with NSCLC and their relevance for personalized care and targeted therapies.

Address identified barriers associated with obtaining adequate tissue samples to support the diagnosis and eventual management of NSCLC.

Improve knowledge, competence, and skills associated with biospecimen collection and the ability to utilize emerging assays to assess for molecular targets associated with NSCLC.

Explicate the role of biomarkers, companion diagnostic tests, and immunotherapy.

Improve ineffective communication pathways and systems-driven “silos” that may impede personalized care for patients with NSCLC.

Enhance interdisciplinary collaboration with identification of optimal use of medical and surgical therapies for NSCLC.

Improve clinician knowledge of recent clinical data on current and emerging therapies for NSCLC, including tumor biomarkers, targeted therapy, and immuno-oncology.

Address barriers to treatment, such as patient comorbidities and therapy side effects.

USD

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Hilton Garden Inn-Atlanta Perimeter Center

1501 Lake Hearn Drive

Atlanta, GA 30319

UNITED STATES

Submission Info

Phone and Fax:

Phone: 224/521-9800 or 800/343-2227 (toll-free in the United States)

Fax: 224/521-9801

Normal business hours: Monday through Friday, 8:30 am CT to 4:00 pm CT.

Mailing Address:

CHEST Global Headquarters 

2595 Patriot Boulevard

Glenview, Illinois 60026 

Phone and Fax:

Phone: 224/521-9800 or 800/343-2227 (toll-free in the United States)

Fax: 224/521-9801

Normal business hours: Monday through Friday, 8:30 am CT to 4:00 pm CT.

Mailing Address:

CHEST Global Headquarters 

2595 Patriot Boulevard

Glenview, Illinois 60026